

Exhibit E

BMS/OTN Price Dispersion

% of Net Revenue at Net Transaction Prices

Blenoxane												Total	Pre-generic	Post-generic
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002				
0 - <50% of WLP												7.6%	0.0%	19.1%
50 - <75% of WLP												27.3%	4.4%	62.0%
75 - <90% of WLP												4.9%	3.2%	7.5%
90 - <95% of WLP												2.7%	4.2%	0.5%
>95% of WLP												57.4%	88.2%	10.9%
Cytosan												Total	Pre-generic	Post-generic
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002				
0 - <50% of WLP												61.6%		61.6%
50 - <75% of WLP												5.5%		5.5%
75 - <90% of WLP												0.4%		0.4%
90 - <95% of WLP												0.1%		0.1%
>95% of WLP												32.4%		32.4%
Cytosan Tablets												Total	Pre-generic	Post-generic
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002				
0 - <50% of WLP												0.2%	0.1%	1.0%
50 - <75% of WLP												4.9%	3.4%	15.1%
75 - <90% of WLP												0.0%	0.1%	0.0%
90 - <95% of WLP												4.3%	4.9%	0.0%
>95% of WLP												90.5%	91.6%	83.9%
Etopophos												Total	Pre-generic	Post-generic
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002				
0 - <50% of WLP												0.0%	0.0%	
50 - <75% of WLP												0.3%	0.3%	
75 - <90% of WLP												0.4%	0.4%	
90 - <95% of WLP														
>95% of WLP												99.3%	99.3%	
Paraplatin												Total	Pre-generic	Post-generic
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002				
0 - <50% of WLP												0.5%	0.5%	
50 - <75% of WLP												2.1%	2.1%	
75 - <90% of WLP												1.8%	1.8%	
90 - <95% of WLP												3.3%	3.3%	
>95% of WLP												92.4%	92.4%	
Rubex												Total	Pre-generic	Post-generic
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002				
0 - <50% of WLP												64.0%		64.0%
50 - <75% of WLP												0.6%		0.6%
75 - <90% of WLP												0.2%		0.2%
90 - <95% of WLP														
>95% of WLP												35.2%		35.2%

Exhibit E

BMS/OTN Price Dispersion

% of Net Revenue at Net Transaction Prices

Taxol	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP											1.4%	0.0%	10.0%
50 - <75% of WLP											2.9%	1.2%	13.6%
75 - <90% of WLP											5.0%	1.5%	26.3%
90 - <95% of WLP											3.6%	1.0%	19.7%
>95% of WLP											87.2%	96.3%	30.4%

VePesid	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP											15.9%	0.0%	44.2%
50 - <75% of WLP											19.6%	12.6%	32.1%
75 - <90% of WLP											11.0%	14.7%	4.3%
90 - <95% of WLP											1.1%	1.3%	0.6%
>95% of WLP											52.5%	71.3%	18.8%

VePesid Capsules	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP											0.5%	0.0%	8.7%
50 - <75% of WLP											5.8%	6.1%	0.6%
75 - <90% of WLP											0.4%	0.4%	0.2%
90 - <95% of WLP											4.3%	4.2%	6.4%
>95% of WLP											89.0%	89.2%	84.0%

All Products	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	Total	Pre-generic	Post-generic
0 - <50% of WLP											2.5%	0.2%	20.5%
50 - <75% of WLP											4.2%	2.1%	19.8%
75 - <90% of WLP											3.9%	2.0%	18.0%
90 - <95% of WLP											3.3%	2.1%	12.7%
>95% of WLP											86.1%	93.6%	29.0%

Sources:

BMS invoice data from SHARP: DirectSales_IncludingPHS.txt
Pre1997-Direct.txt

OTN invoice data: OTN Blenoxane.txt OTN Blenoxane_Pre1997.txt
OTN Cytoxan.txt OTN Cytoxan_Pre1997.txt
OTN Etopophos.txt OTN Etopophos_Pre1997.txt
OTN Paraplatin.txt OTN Paraplatin_Pre1997.txt
OTN Rubex.txt OTN Rubex_Pre1997.txt
OTN Taxol.txt OTN Taxol_Pre1997.txt
OTN Vepesid.txt OTN Vepesid_Pre1997.txt

BMS chargeback data: Chargebacks_IncludingPHS.txt
Pre1997-Indirect.txt

Wholesale List Price: PricingRevised.xls
buspar_rubex.xls

Notes:

Post-generic shares are calculated from years in which a generic was available for the entire year
See Exhibit C for an explanation of the underlying price calculations and the shares shown above